An observational study in Hypertension, Diabetes Mellitus and Chronic Kidney Disease, sponsored by National Yang Ming Chiao Tung University. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by National Yang Ming Chiao Tung University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Hypertension with a site in Taiwan — 17 open to participants now, 21 under way, 5 of them phase 3. Hypertension · Taiwan.
Among the 117 studies in Hypertension with a site in Taiwan, this one is the 21st largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2026, is one of 27 observational ones, reaches primary completion later than 5 of the 20 other live ones, and was the 114th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →17 of the 117 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 18+
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 50+
Kaohsiung Armed Forces General Hospital · Sites in Taiwan
Ages 18–65
New Taipei City Medical Association · Sites in Taiwan
Medtronic Vascular · Sites in Taiwan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 27 · Phase 4 20
First in 2001; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 233 across the 90 interventional studies, 156 across the 25 observational. Of the 76 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 117 have an industry lead sponsor. The 10 most frequent:
National Yang Ming Chiao Tung University is the lead sponsor of 208 studies on the registry; 58 are open to participants now.
National Yang Ming Chiao Tung University has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
8 of the studies in Hypertension with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07543211National Yang Ming Chiao Tung UniversityEffectiveness of Laser Irradiation on the Veins and Acupoints on Arterial Stiffness in Patients With Cardio-renal Metabolic Syndrome | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07578090Fu Jen Catholic UniversityRegional Innovation in Chronic Disease and Elderly Care | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 117 studies in Hypertension with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Cardio-renal metabolic syndrome (CRMS) is a vicious cycle of cardiac, renal, and metabolic disease, representing a high-risk for atherosclerosis. Laser acupuncture modulates vascular inflammation and improves endothelial function via low-level laser therapy (LLLT, \<500mW) at acupoints or musculoskeletal pain sites. Few studies have focused on CRMS populations. This study evaluates laser acupuncture effects on arterial stiffness in CRMS.
Purpose: To assess the effects of improvement of laser acupuncture in patients with CRMS, and to evaluate its feasibility as supportive therapy.
Methods: A single-group pre-post design is used. Participants are patients with CRMS receiving laser acupuncture at a Chinese medicine clinic in Taiwan. CRMS is interrelated by cardiac, renal, and metabolic disease. Inclusion criteria require diagnosis in ≥2 of 3 systems (cardiovascular, renal, or metabolic; n = 35). Laser acupuncture will be applied to bilateral BL40 for 12 weeks (1-3 sessions/week, 60mins/session). Pulse wave velocity(PWV) measured by Omron HBP- 8000 as the primary outcome for arterial stiffness. Paired t-tests and GEE will be used for analysis.
Expected Results: PWV is expected to show significant improvement after intervention.
Participants are adult patients diagnosed with cardio-renal-metabolic syndrome who are receiving routine laser acupuncture treatment in a clinical setting. The study population includes individuals with conditions such as hypertension, diabetes mellitus, chronic kidney disease, or dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low-level laser therapy applied to acupuncture points as part of routine clinical treatment. No additional intervention is assigned for research purposes.
Change in Pulse Wave Velocity (PWV)
Time frame: Baseline and after 12 weeks of treatment
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 7 months is below that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Aug 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Yang Ming Chiao Tung University →